A bill to amend title XI of the Social Security Act to require that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information.

Bill 119 s 229, also known as the "Drug Price Transparency Act," aims to amend title XI of the Social Security Act to mandate that direct-to-consumer advertisements for prescription drugs and biological products must include pricing information. This bill seeks to increase transparency in the pharmaceutical industry by ensuring that consumers are informed about the costs of the medications they see advertised.

The bill would require that pricing information be clearly disclosed in any direct-to-consumer advertisements for prescription drugs and biological products. This information would include the list price of the medication, as well as any out-of-pocket costs that consumers may incur. By providing this pricing information upfront, the bill aims to empower consumers to make more informed decisions about their healthcare and potentially reduce the financial burden of prescription medications.

Proponents of the bill argue that increased transparency in drug pricing will help to hold pharmaceutical companies accountable for their pricing practices and may ultimately lead to lower drug costs for consumers. However, opponents of the bill raise concerns about the potential impact on the pharmaceutical industry, including the possibility of decreased advertising and innovation in drug development. Overall, Bill 119 s 229 represents a significant step towards increasing transparency in the pharmaceutical industry and empowering consumers to make more informed decisions about their healthcare. It will be important to closely monitor the implementation of this bill and assess its impact on drug pricing and consumer behavior.